Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboringBRAFmutations in the Lung Cancer Mutation Consortium

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer

(2013) S. Cardarella et al.   CLINICAL CANCER RESEARCH

Dramatic Response Induced by Vemurafenib in aBRAFV600E-Mutated Lung Adenocarcinoma

(2013) Solange Peters et al.   JOURNAL OF CLINICAL ONCOLOGY

A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations

(2013) Doraid Alrifai et al.   LUNG CANCER

Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma

(2012) Shengxiang Ren et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

(2012) S. Dogan et al.   CLINICAL CANCER RESEARCH

The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer

(2012) Stephanie Cardarella et al.   Journal of Thoracic Oncology

A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib

(2012) Oliver Gautschi et al.   Journal of Thoracic Oncology

Vemurafenib: the first drug approved for BRAF-mutant cancer

(2012) Gideon Bollag et al.   NATURE REVIEWS DRUG DISCOVERY

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

(2011) L. V. Sequist et al.   ANNALS OF ONCOLOGY

The GeneInsight suite: a platform to support laboratory and provider use of DNA-based genetic testing

(2011) Samuel J. Aronson et al.   HUMAN MUTATION

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations

(2011) Antonio Marchetti et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations

(2011) Paul K. Paik et al.   JOURNAL OF CLINICAL ONCOLOGY

A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer

(2011) Zengliu Su et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling

(2011) J. E. Chaft et al.   MOLECULAR CANCER THERAPEUTICS

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

(2010) H. Yang et al.   CANCER RESEARCH

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

(2008) G. J. Riely et al.   CLINICAL CANCER RESEARCH